A leading personal genetics company.

The analysis controlled for age group, genetic ancestry, breast surgeries, breast feeding pregnancy and status history. The 23andMe analysis platform is a robust source of new genetic discoveries which study demonstrates that important scientific insights will come from the most unlikely places, mentioned 23andMe co-founder and CEO Anne Wojcicki. Nearly 90 % of our more than 150,000 customers participate in our online analysis allowing 23andMe to create discoveries faster and more cost effectively than traditional research models, added Wojcicki. While some factors of breast morphology, such as for example density, are known to be directly implicated in breasts cancer, the partnership between breast cancer and size is less clear. While breasts size is heritable, this scholarly study is the first to recognize genetic variants linked to differences in breast size.Kaiser Health News, an independent news service editorially, is a scheduled program of the Kaiser Family Foundation, a nonpartisan healthcare policy research business unaffiliated with Kaiser Permanente., the leader in the development of selective histone deacetylase inhibitors for improved therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept scientific trials with selective HDAC6 inhibitor, ricolinostat , were shown at the 55th Annual Achieving of the American Society of Hematology in New Orleans, LA.